- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Off-Label Drug Use and Adverse Drug Events
What we're reading, November 3, 2015: off-label drug use is associated with a higher risk of adverse drug events; CMS finalizes its rule for advanced care planning for end-of-life care; and Californians send measure to cut drug prices to the vote.
Off-Label Drug Use Associated With Higher Adverse Drug Event Risk
A study published in JAMA Internal Medicine suggested caution when prescribing drugs for off-label use when there is a lack of strong evidence as the practice is associated with adverse drug events. While the overall rate of adverse drug events for off-label use was higher than that for on-label use, off-label use with strong scientific evidence had the same risk as on-label use. Risk for adverse events were higher for drugs approved between 1981 and 1995, and for those used by women, patients receiving 5 to 7 drugs, and patients receiving cardiovascular drugs.
CMS Finalizes Rule to Plan for End-of-Life Care
After receiving comments supporting the proposed rule to enable physicians to discuss advance care planning with Medicare beneficiaries, CMS is finalizing the rule. Advanced care discussions about how a patient would like to be care for when they are dying can occur early, before an illness progresses, or during the course of treatment. CMS is also finalizing payment for advance care planning when it is part of the Annual Wellness Visit.
California Measure Curbing Drug Costs Will Go to Vote
In California, advocates of a proposed measure that would slash drug prices receive more than enough signatures to place the measure on the ballot in November 2016. The proposed measure would require that programs where the state pays for a drug, even if the state did not purchase the drug directly, would pay no more than the price negotiated by the US Department of Veterans Affairs, reported San Jose Mercury News.
Trump Administration’s Message to Supreme Court Puts New Wrinkle in Braidwood Case
February 21st 2025The Trump administration argues that HHS Secretary Robert F. Kennedy Jr can overrule the US Preventive Services Task Force to determine the preventive services covered under the Affordable Care Act.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
5 Key Health Care Moments During President Trump's First Month Back in Office
February 21st 2025President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive orders affecting managed care, drug pricing, and clinical trial diversity guidance.
Read More
Adapting ACA Access Amid Medicaid Transition and Policy Reversals: Molly Dean
February 19th 2025As enrollment shifts to the Affordable Care Act (ACA) marketplace following the unwinding of Medicaid and the Trump administration begins to implement health policy changes, Molly Dean, MSW, Siftwell's policy advisor, shares insight on how to adapt.
Read More
